Natco Pharma announced that the Appeals Court in the US has rejected its marketing partner Alvogens appeal on Ibrutinib Tablets of 140 mg, 280 mg, 420 mg and 560 mg strength (proposed generic equivalents to Imbruvica? Tablets). Natco and its co-development & marketing partner, Alvogen Pine Brook LLC, USA, are assessing their option on the way forward.Powered by Capital Market – Live News
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
